MicroRNA-195 predicts olanzapine response in drug-free patients with schizophrenia: A prospective cohort study

作者：Xinxin Huang, Chenxi Bao, Qinyu Lv, Jing Zhao, Guoqin Hu, Haisu Wu, Zezhi Li, Zhenghui Yi · 发表于：Journal of Psychopharmacology · 年份：2020 · DOI：10.1177/0269881120959617 · 被引用次数：15 · 研究领域：MicroRNA in disease regulation、Tryptophan and brain disorders、Schizophrenia research and treatment

Background: Disturbances of microRNA-195 have been implicated in the pathogenesis of schizophrenia. However, microRNA-195 levels in schizophrenia are controversial. Aims: To the best of our knowledge, this is the first study to examine microRNA-195 levels in untreated schizophrenia patients and their relationship to olanzapine response. Methods: We recruited 81 untreated schizophrenia patients and 96 healthy controls. The patients received 2 months olanzapine treatment. MicroRNA-195 levels in peripheral blood mononuclear cells were measured using quantitative real-time polymerase chain reaction testing. Psychiatric symptoms were assessed using the Positive and Negative Syndrome Scale. Results: No significant differences in microRNA-195 levels were found between patients and healthy controls ( p > 0.05). Olanzapine significantly reduced microRNA-195 levels after 2 months treatment ( p = 0.003). Interestingly, microRNA-195 levels decreased significantly in responders ( p = 0.010), but not in non-responders ( p > 0.05). Both baseline microRNA-195 levels ( p = 0.027, p = 0.030) and the reduction rate of microRNA-195 levels ( p = 0.034, p = 0.044) were positively associated with the reduction rate of Positive and Negative Syndrome Scale total score and general psychopathological subscale score. Multiple stepwise regression analysis revealed that baseline microRNA-195 level was an independent contributor to the reduction in Positive and Negative Syndrome Scale total score and...